Alveolar lipids in pulmonary disease. A review
Abstract Lung lipid metabolism participates both in infant and adult pulmonary disease. The lung is composed by multiple cell types with specialized functions and coordinately acting to meet specific physiologic requirements. The alveoli are the niche of the most active lipid metabolic cell in the l...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12944-020-01278-8 |
id |
doaj-cb1cabd2263b47c5a7231392eba34b6e |
---|---|
record_format |
Article |
spelling |
doaj-cb1cabd2263b47c5a7231392eba34b6e2020-11-25T03:53:50ZengBMCLipids in Health and Disease1476-511X2020-06-0119112110.1186/s12944-020-01278-8Alveolar lipids in pulmonary disease. A reviewChristina W. Agudelo0Ghassan Samaha1Itsaso Garcia-Arcos2Department of Medicine, SUNY Downstate Health Sciences UniversityDepartment of Medicine, SUNY Downstate Health Sciences UniversityDepartment of Medicine, SUNY Downstate Health Sciences UniversityAbstract Lung lipid metabolism participates both in infant and adult pulmonary disease. The lung is composed by multiple cell types with specialized functions and coordinately acting to meet specific physiologic requirements. The alveoli are the niche of the most active lipid metabolic cell in the lung, the type 2 cell (T2C). T2C synthesize surfactant lipids that are an absolute requirement for respiration, including dipalmitoylphosphatidylcholine. After its synthesis and secretion into the alveoli, surfactant is recycled by the T2C or degraded by the alveolar macrophages (AM). Surfactant biosynthesis and recycling is tightly regulated, and dysregulation of this pathway occurs in many pulmonary disease processes. Alveolar lipids can participate in the development of pulmonary disease from their extracellular location in the lumen of the alveoli, and from their intracellular location in T2C or AM. External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD), and others. Sustained damage to the T2C is one of the postulated causes of idiopathic pulmonary fibrosis (IPF), and surfactant homeostasis is disrupted during fibrotic conditions. Similarly, surfactant homeostasis is impacted during acute respiratory distress syndrome (ARDS) and infections. Bioactive lipids like eicosanoids and sphingolipids also participate in chronic lung disease and in respiratory infections. We review the most recent knowledge on alveolar lipids and their essential metabolic and signaling functions during homeostasis and during some of the most commonly observed pulmonary diseases.http://link.springer.com/article/10.1186/s12944-020-01278-8LungsAlveoliSurfactantIPFCOPDLipids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christina W. Agudelo Ghassan Samaha Itsaso Garcia-Arcos |
spellingShingle |
Christina W. Agudelo Ghassan Samaha Itsaso Garcia-Arcos Alveolar lipids in pulmonary disease. A review Lipids in Health and Disease Lungs Alveoli Surfactant IPF COPD Lipids |
author_facet |
Christina W. Agudelo Ghassan Samaha Itsaso Garcia-Arcos |
author_sort |
Christina W. Agudelo |
title |
Alveolar lipids in pulmonary disease. A review |
title_short |
Alveolar lipids in pulmonary disease. A review |
title_full |
Alveolar lipids in pulmonary disease. A review |
title_fullStr |
Alveolar lipids in pulmonary disease. A review |
title_full_unstemmed |
Alveolar lipids in pulmonary disease. A review |
title_sort |
alveolar lipids in pulmonary disease. a review |
publisher |
BMC |
series |
Lipids in Health and Disease |
issn |
1476-511X |
publishDate |
2020-06-01 |
description |
Abstract Lung lipid metabolism participates both in infant and adult pulmonary disease. The lung is composed by multiple cell types with specialized functions and coordinately acting to meet specific physiologic requirements. The alveoli are the niche of the most active lipid metabolic cell in the lung, the type 2 cell (T2C). T2C synthesize surfactant lipids that are an absolute requirement for respiration, including dipalmitoylphosphatidylcholine. After its synthesis and secretion into the alveoli, surfactant is recycled by the T2C or degraded by the alveolar macrophages (AM). Surfactant biosynthesis and recycling is tightly regulated, and dysregulation of this pathway occurs in many pulmonary disease processes. Alveolar lipids can participate in the development of pulmonary disease from their extracellular location in the lumen of the alveoli, and from their intracellular location in T2C or AM. External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD), and others. Sustained damage to the T2C is one of the postulated causes of idiopathic pulmonary fibrosis (IPF), and surfactant homeostasis is disrupted during fibrotic conditions. Similarly, surfactant homeostasis is impacted during acute respiratory distress syndrome (ARDS) and infections. Bioactive lipids like eicosanoids and sphingolipids also participate in chronic lung disease and in respiratory infections. We review the most recent knowledge on alveolar lipids and their essential metabolic and signaling functions during homeostasis and during some of the most commonly observed pulmonary diseases. |
topic |
Lungs Alveoli Surfactant IPF COPD Lipids |
url |
http://link.springer.com/article/10.1186/s12944-020-01278-8 |
work_keys_str_mv |
AT christinawagudelo alveolarlipidsinpulmonarydiseaseareview AT ghassansamaha alveolarlipidsinpulmonarydiseaseareview AT itsasogarciaarcos alveolarlipidsinpulmonarydiseaseareview |
_version_ |
1724476379792146432 |